Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Down Syndrome Stories

2012-02-27 13:00:00

WASHINGTON, Feb. 27, 2012 /PRNewswire-USNewswire/ -- New Jersey Governor First Lady Mary Pat Christie and other Governor First Spouses will again be joining together to bring attention to Down syndrome cognitive research, a rapidly advancing area of research that holds great promise for improving memory, learning and communication for individuals of all ages with Down syndrome. The First Spouse "Light the Way" event will be observed on World Down Syndrome Day, March 21, 2012....

2012-02-23 07:00:00

REDWOOD CITY, Calif., Feb. 23, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today published the full data from its prospective, blinded, multicenter clinical validation study to detect fetal chromosomal aneuploidies across the entire genome, including cases of fetal mosaicism and translocations. The publication, entitled "Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing," was selected as Editor's Choice...

2012-02-13 09:00:00

REDWOOD CITY, Calif., Feb. 13, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the presentation of top-line results from its prospective, blinded, multicenter validation study to detect fetal chromosomal aneuploidies, or an abnormal number of chromosomes, across the entire genome. The study was specifically designed to include all samples with any abnormal karyotype in order to emulate real-world testing in which...

2012-02-10 14:32:58

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting , in Dallas, Texas, researchers will report findings that indicate that massively parallel sequencing can be used to diagnose fetal aneuploidies, including Down syndrome, Edwards syndrome, Patau syndrome and Turner syndrome. Because of the importance of the clinical data, the abstract, entitled Genome Wide Fetal Aneuploidy Detection by Sequencing of Maternal Plasma DNA:...

2012-01-27 13:00:00

CHICAGO, Jan. 27, 2012 /PRNewswire-USNewswire/ -- Research Down Syndrome (RDS), a nonprofit foundation that is among the leading sources for funding of Down syndrome related cognitive research, is entering the second year of its national running program, Race for the Extraordinary, to help increase public awareness and funding for Down syndrome research. The mission of RDS is the development of safe and effective therapies to address the intellectual difficulties associated with...

2012-01-27 08:00:00

SAN JOSE, Calif., Jan. 27, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, today announced the publication of a study showing that Aria's technology -- a directed non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood using a proprietary algorithm -- enabled non-invasive detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome). The data appear online in the American Journal of Obstetrics...

2012-01-26 11:00:00

SAN JOSE, Calif., Jan. 26, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, today announced the publication of an independent blinded study that examines the accuracy of its non-invasive prenatal test for the detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome). The study showed that the test, coupled with a proprietary algorithm to assess individualized risk for these trisomies, distinguished 100...

2012-01-12 08:00:00

SAN JOSE, Calif., Jan. 12, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, announced that it is initiating a blinded, multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal translucency ultrasound alone and in combination) to detect Trisomy 21, which is associated with Down syndrome. Aria's test, which is currently in development, uses a directed,...

2012-01-09 19:08:55

Aria Diagnostics (formerly Tandem Diagnostics), a molecular diagnostics company, today announced publication of data supporting a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood for evaluation of two common fetal trisomies linked to genetic disorders. The results, assessing the detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome), were published online at...

2012-01-09 08:00:00

SAN JOSE, Calif., Jan. 9, 2012 /PRNewswire/ -- Aria Diagnostics (formerly Tandem Diagnostics), a molecular diagnostics company, today announced publication of data supporting a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood for evaluation of two common fetal trisomies linked to genetic disorders. The results, assessing the detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome), were published online...